Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)

Leukemia and Lymphoma

Volumn 56, Issue 4, 2015, Pages 958-964

  Morrison, Vicki A ^a   Jung, Sin Ho ^b   Johnson, Jeffrey ^b   Lacasce, Ann ^c   Blum, Kristie A ^d   Bartlett, Nancy L ^e   Pitcher, Brandelyn N ^b   Cheson, Bruce D ^f  

^a UNIVERSITY OF MINNESOTA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Bortezomib; Lenalidomide; Mantle cell lymphoma

Indexed keywords

BORTEZOMIB; HEMOGLOBIN; LENALIDOMIDE; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ADULT; AGED; ANOREXIA; ARTICLE; CONSTIPATION; DESQUAMATION; DIARRHEA; DIZZINESS; DRUG WITHDRAWAL; DYSPNEA; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; INDUCTION CHEMOTHERAPY; INFECTION; LEUKOCYTE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; REFRACTORY PERIOD; RELAPSE; REMISSION; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTE; THROMBOSIS; TREATMENT DURATION; VERY ELDERLY; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG RESISTANCE; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; NEUROLOGIC DISEASE; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, MANTLE-CELL; LYMPHOPENIA; MALE; MIDDLE AGED; NAUSEA; NERVOUS SYSTEM DISEASES; RECURRENCE; REMISSION INDUCTION; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84929119124     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.938333     Document Type: Article

References (35)

1. Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008;113:791-798.
2. Chandran R, Gardiner SK, Simon M, et al. Survival trends in mantle cell lymphoma in the United States over sixteen years 1992-2007. Leuk Lymphoma 2012;53:1488-1493.
3. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27:1209-1213.
4. Vose J M. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am J Hematol 2012;87:605-609.
5. Ruan J, Coleman M, Leonard J P. Management of relapsed mantle cell lymphoma: still a treatment challenge. Oncology 2009;23:683-690.
6. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an openlabel, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;38:1203-1210.
7. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511-518.
8. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-4427.
9. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-684.
10. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-675.
11. Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007;18:116-121.
12. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-4874.
13. Wiernik P H, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4952-4957.
14. Zinzani PL, Witzig TE, Vose J, et al. Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle cell lymphoma: Results of an international study (NHL-003). Blood 2008;112:262-267.
15. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145:344-349.
16. Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013;31:3688-3695.
17. Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009;27:5713-5719.
18. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
19. Jung SH, Kim KM. On the estimation of the binomial probability in multistage clinical trials. Stat Med 2004;23:881-896.
20. Jennison C, Turnbull BW. Confidence intervals for a binomial parameter following a multistage test with application to MIL-STD 105D and medical trials. Technometrics 1983;25:49-58.
21. Jung SH, Owzar K, George SL, et al. P-value calculation for multistage phase II cancer clinical trials (with discussion). J Biopharm Stat 2006;16:765-783.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
23. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20:520-525.
24. Lamm W, Kaufmann H, Raderer M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 2011;96:1008-1014.
25. Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/ refractory mantle cell lymphoma. Blood 2004;104:2269-2271.
26. Williams ME. Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: subgroup analysis of the MCL-001 study. J Clin Oncol 2013;31(15 Suppl.): Abstract 8534.
27. Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol 2012;159:154-163.
28. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18:317-324.
29. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle cell lymphoma. N Engl J Med 2012;367:520-531.
30. Wang M, Fayad L, Wagner-Bartak N, et al. Oral lenalidamide plus 4 doses of rituximab induced prolonged remissions in relapsed/ refractory mantle cell lymphoma: a completed phase I/II clinical trial. Ann Oncol 2011;22(Suppl.):109a.
31. Rummel M, Atta J, Welslau M. Bendamustine and rituximab (BR) are effective in the treatment of relapsed or refractory indolent and mantle-cell lymphomas: long term follow up of a phase II study. J Clin Oncol 2007;25(Suppl.):8034a.
32. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473-4479.
33. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822-3829.
34. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507-516.
35. Kahl BS, Byrd JC, Flinn IW, et al. Clinical safety and efficacy in a phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110delta, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2010;116(Suppl. 1): Abstract 1777.